X4 Pharmaceuticals, Inc. filings document a rare-disease biopharmaceutical issuer with commercial activity for XOLREMDI and development work around mavorixafor. Its 8-K reports cover operating and financial results, material agreements, restructuring actions, executive and board changes, and capital-structure updates involving common stock, pre-funded warrants, registration rights, and equity purchase arrangements.
Proxy materials describe shareholder voting matters, board composition, committee assignments, executive compensation, equity awards, and governance procedures. The filing record also includes disclosures tied to the company’s inducement and equity incentive practices, financing arrangements, and formal reporting of material corporate events.
X4 Pharmaceuticals, Inc. reported nine-month 2026 revenue of $14.4 million, compared with $32.5 million a year earlier, while U.S. product revenue rose to $7.6 million from $4.3 million. Net loss was $56.6 million versus $55.3 million, and net cash used in operations was $60.6 million.
XOLREMDI (mavorixafor) is approved in the U.S. and EU for WHIM syndrome. The FDA said the revised 4WARD Phase 3 enrollment target of 126, down from 176, maintains adequate overall power for the co-primary endpoints; the proposed safety database appears acceptable for a potential sNDA, though its adequacy remains a review issue. X4 expects enrollment completion by year-end 2026. Its 4STEPS Phase 2b trial is designed for approximately 25 patients, with top-line data expected in the first quarter of 2028.
On October 7, X4 funded an $80.0 million first tranche under a K2 loan agreement and used substantially all proceeds to repay Hercules. K2 provides up to $150.0 million, including another $70.0 million subject to company request, agent review and lenders’ discretionary approval. Cash, equivalents and short-term marketable securities totaled $187.7 million as of September 30; X4 believes its resources as of November 4 will fund operations and debt obligations for at least 12 months.
X4 Pharmaceuticals, Inc. outlined mavorixafor development in primary chronic neutropenia (PCN). The ongoing global, double-blind, placebo-controlled Phase 3 4WARD trial is designed for 126 patients; X4 expects full enrollment by the end of Q4 2026 and topline data in Q1 2028. Primary endpoints are ANC response and annualized infection rate. X4 describes potential U.S. FDA approval in late 2028 or early 2029 and states that safety and efficacy in PCN have not been established.
X4 plans to start the Phase 2b 4STEPS study in Q1 2027, evaluating G-CSF dose reduction with mavorixafor in acquired primary autoimmune and idiopathic chronic neutropenia disorders. The single-arm, open-label study has estimated enrollment of ~25 patients; topline data are expected in H1 2028, with efficacy measures including G-CSF cessation and dosage reduction at six months.
X4 cites claims analyses estimating ~15,000 symptomatic U.S. patients with ANC <1,000 cells/µL and 2+ infections in 2025, and ~95,000 patients aged 12+ with confirmed PCN and ANC <1,500 cells/µL active in 2025. For WHIM syndrome, XOLREMDI launched in the U.S. in 2024 and received European Commission approval in 2026. X4 says its cash runway is expected into 2029.
X4 Pharmaceuticals, Inc. Executive Chairman and director Adam R. Craig directly purchased 4,600 shares of common stock on October 16, 2026, at $2.5834 per share. His reported direct position after the purchase was 333,251 shares; of the reported common-stock position, 193,254 shares represent restricted stock units. No Rule 10b5-1 plan is reported.
X4 Pharmaceuticals, Inc. entered into a senior secured term loan facility with K2 HealthVentures for up to $150.0 million. The lenders funded $80.0 million on October 7, 2026; up to $70.0 million more may be made available at the Borrowers’ request, subject to the Administrative Agent’s review of certain information and the Lenders’ discretionary approval. The Borrowers used part of the funded tranche to repay their Hercules facility in full for approximately $78.7 million, including $75.0 million of principal.
The loans bear cash interest at the greater of 8.55% or The Wall Street Journal prime rate plus 1.55%, and 1.0% annual paid-in-kind interest. Interest-only payments run through October 1, 2029, with extension to maturity conditional on, among other conditions, first U.S. commercial sales of mavorixafor for moderate to severe chronic neutropenia; maturity is October 1, 2030. The Lenders may convert up to $15.0 million of principal into common stock at $3.2341 per share, subject to beneficial ownership limitations. The loans are secured by substantially all Borrowers’ assets except intellectual property.
X4 Pharmaceuticals, Inc. common stock was reported as beneficially owned by FMR LLC and Abigail P. Johnson, each with 4,558,616 shares, or 4.6% of the class. FMR LLC reported sole voting power over 4,558,586 shares and sole dispositive power over 4,558,616 shares. Abigail P. Johnson reported zero voting power and sole dispositive power over 4,558,616 shares.
X4 Pharmaceuticals, Inc. Chief Financial Officer David Kirske reported selling 11,767 shares of common stock on October 1, 2026, at a weighted average price of $2.8604 per share. The sale covered a personal income tax obligation upon settlement of a restricted stock unit award. No Rule 10b5-1 plan is reported. His reported holdings afterward were 155,983 shares, including 64,418 shares that represent restricted stock units.
X4 Pharmaceuticals, Inc. officer David Kirske reported a proposed sale of 11,767 common shares, with an aggregate market value of $33,658.47. The notice lists October 1, 2026, as the approximate sale date and Morgan Stanley Smith Barney LLC as the broker. The sale is described as required to cover tax withholding on vested restricted stock units under the issuer’s equity incentive plans, not as a discretionary trade. A separate line lists 32,209 shares acquired through restricted stock unit vesting on September 30, 2026.
X4 Pharmaceuticals, Inc. (XFOR) is the subject of a Schedule 13G reporting that a group of Venrock-affiliated funds and individuals collectively beneficially own 5,555,047 shares of its common stock. This represents 5.6% of X4’s common shares, based on 99,146,743 shares outstanding as of July 31, 2026.
The reported holdings consist of 2,553,145 shares held by Venrock Healthcare Capital Partners III, L.P., 255,515 shares held by VHCP Co-Investment Holdings III, LLC, and 2,746,387 shares held by Venrock Healthcare Capital Partners EG, L.P. The reporting entities and individuals share voting and dispositive power over these shares as a group.
X4 Pharmaceuticals, Inc. (XFOR) furnished an updated corporate presentation outlining the status of mavorixafor (XOLREMDI), its oral CXCR4 antagonist, and its strategy in chronic neutropenia and WHIM syndrome. Mavorixafor is already approved for WHIM syndrome in the U.S. and EU, and X4 is focusing on a pivotal Phase 3 4WARD trial in chronic neutropenia.
The presentation states that full enrollment in the 4WARD study is expected in Q4 2026, with top-line data in H1 2028 and potential U.S. FDA approval in late 2028 or early 2029. The trial plans to enroll 126 patients with moderate or severe chronic neutropenia and assesses ANC response and annualized infection rate as co-primary endpoints. Phase 2 data showed increases in mean absolute neutrophil counts to normal levels and substantial reductions in G-CSF use, with mainly mild to moderate gastrointestinal adverse events.
The company highlights a U.S. target market of about 15,000 primary chronic neutropenia patients with moderate and severe disease, positioning mavorixafor as monotherapy or in combination with G-CSF. X4 reports raising $240 million from institutional investors, holding $208 million of cash as of June 30, 2026, with a cash runway expected into 2029 and patent protection for mavorixafor expected through 2038.
X4 Pharmaceuticals, Inc. (XFOR) reports a positive outcome from a Type C Meeting with the U.S. Food and Drug Administration regarding its global 4WARD Phase 3 trial of mavorixafor in chronic neutropenia. The FDA agreed with X4’s analysis to reduce the 4WARD trial sample size from 176 to 126 participants while maintaining adequate overall power for the co-primary endpoints of reduced annualized infection rate and positive absolute neutrophil count (ANC) response. The FDA also indicated that the proposed safety database would be acceptable to support a potential supplemental new drug application (sNDA).
X4 states that, with support from its new clinical research organization, it expects to complete enrollment in 4WARD by the end of 2026 and to report topline data in the first half of 2028. The company highlights an estimated 15,000 patients with serious and/or recurring infections from chronic neutropenia as a potential market and notes that mavorixafor, an oral CXCR4 antagonist already available in the U.S. as XOLREMDI in a first indication, has U.S. FDA Fast Track designation for chronic neutropenia.